The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Phase I trial of MCARH109, a GPRC5D-directed CAR T-cell, for patients with R/R multiple myeloma
Eric Jurgens, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares updated results from a Phase I trial exploring the safety and efficacy of MCARH109, a GPRC5D-directed CAR T-cell therapy, for patients with relapsed/refractory (R/R) multiple myeloma. Overall, 12 out of 17 patients responded, with a median duration of response of 8.6 months and a three-year overall survival (OS) estimate of 59%. The study also reveals potential GPRC5D antigen escape, suggesting the need for alternative targeting strategies to enhance patient responses. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
